.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,750,028

« Back to Dashboard

Claims for Patent: 7,750,028

Title:Crystal modifications of 1-(2,6-difluorobenzyl)-1H-1, 2,3-triazole-4-carboxamide
Abstract: The invention relates to the novel modifications B and C of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide of the formula ##STR00001## its use and pharmaceutical preparations comprising this crystal modifications.
Inventor(s): Portmann; Robert (Pratteln, CH), Hofmeier; Urs C (St. Pantaleon, CH), Burkhard; Andreas (Basel, CH), Scherrer; Walter (Rheinfelden, CH), Szelagiewicz; Martin (Munchenstein, CH)
Assignee: Novartis AG (Basel, CH)
Application Number:11/329,945
Patent Claims: 1. A method of treating epilepsy comprising administering to a subject in need of such treatment a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide of the formula ##STR00003## characterized by characteristic lines at interplanar spacings (d values) of 10.5 .ANG., 5.14 .ANG., 4.84 .ANG., 4.55 .ANG., 4.34 .ANG., 4.07 .ANG., 3.51 .ANG., 3.48 .ANG., 3.25 .ANG., 3.19 .ANG., 3.15 .ANG., 3.07 .ANG. and 2.81 .ANG., as determined by means of an X-ray powder pattern.

2. A method according to claim 1 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1 -(2,6-difluorobenzyl )-1H-1,2,3-triazole-4-carboxamide characterized by an X-ray powder pattern having the following characteristic lines at interplanar spacings (d values) of 10.9 .ANG. (weak), 10.5 .ANG. (medium), 6.6 .ANG. (weak), 5.63 .ANG. (weak), 5.25 .ANG. (weak), 5.14 .ANG. (medium). 4.94 .ANG. (weak), 4.84 .ANG. (very strong), 4.55 .ANG. (strong), 4.42 .ANG. (very weak), 4.34 .ANG. (medium), 4.23 .ANG. (very weak), 4.16 .ANG. (weak), 4.07 .ANG. (medium), 4.01 .ANG. (weak), 3.68 .ANG. (very weak), 3.64 .ANG. (very weak), 3.60 .ANG. (weak), 3.56 .ANG. (weak), 3-51 .ANG. (medium), 3.48 .ANG. (medium), 3.38 .ANG. (very weak), 3.25 .ANG. (strong), 3.19 .ANG. (medium), 3.15 .ANG. (medium), 3.11 .ANG. (weak), 3.07 .ANG. (medium), 2.93 .ANG. (very weak), 2.87 .ANG. (very weak), 2.81 .ANG. (medium), 2.76 .ANG. (weak), 2.73 .ANG. (very weak), 2.68 .ANG. (weak), 2.62 .ANG. (very weak), 2.53 .ANG. (weak), 2,43 .ANG. (weak) and 2.40 .ANG. (very weak).

3. A method according to claim 1 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1 -(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide characterized by absorption bands at 3412 cm.sup.-1 and 3092 cm.sup.-1 in the FT-IR spectrum (KBr pellet-transmission method).

4. A method according to claim 3 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-IH-1,2,3-triazole-4-carboxamide characterized by the following absorption bands in the FT-IR spectrum (KBr pellet-transmission method): 3412, 3189, 3092, 1634, 1560, 1473, 1397, 1325, 1300, 1284, 1235, 1125, 1053, 1036, 1014, 885, 840, 799, 781, 723, 688 and 640 cm.sup.-1.

5. A method according to claim 1 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2.6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide characterized by an endothermic peak in the range from 230.degree. C. to 260.degree. C., the peak temperature being 239-245.degree. C. and the endothermic signal being 209 J/g .+-.10 J/g.

6. A method according to claim 1 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide characterized by an absorption band at 1080 cm.sup.-1 in the FT-Raman spectrum.

7. A method according to claim 6 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2,6-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide characterized by the following absorption bands in the FT-Raman spectrum (powder-reflection method 180.degree.): 3093, 2972, 1628, 1614, 1558, 1466, 1446, 1393, 1279, 1245, 1147, 1080, 1061, 1036, 1014, 840, 724, 691, 667, 550, 499, 437 and 368 cm.sup.-1.

8. A method according to claim 1 comprising administering a pharmaceutical composition, comprising a pharmaceutically acceptable carrier or diluent and a therapeutically effective amount of crystal modification A of the compound 1-(2.8-difluorobenzyl)-1 H-1,2,3-triazole-4-carboxamide in essentially pure form.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc